{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:13:23Z","timestamp":1770506003122,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,5,31]],"date-time":"2013-05-31T00:00:00Z","timestamp":1369958400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s10792-013-9807-6","type":"journal-article","created":{"date-parts":[[2013,5,30]],"date-time":"2013-05-30T03:55:32Z","timestamp":1369886132000},"page":"597-601","source":"Crossref","is-referenced-by-count":10,"title":["Corneal endothelial safety following subconjunctival and intrastromal injection of bevacizumab for corneal neovascularization"],"prefix":"10.1007","volume":"34","author":[{"given":"Alejandro","family":"Lichtinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia N.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maoz D.","family":"Amiran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uri","family":"Elbaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan R.","family":"Slomovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,31]]},"reference":[{"issue":"9","key":"9807_CR1","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1097\/ICO.0b013e31817c41e3","volume":"27","author":"CX Qian","year":"2008","unstructured":"Qian CX, Bahar I, Levinger E, Rootman D (2008) Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization. Cornea 27(9):1090\u20131092","journal-title":"Cornea"},{"issue":"10","key":"9807_CR2","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/ICO.0b013e318180e50f","volume":"27","author":"G Gerten","year":"2008","unstructured":"Gerten G (2008) Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery. Cornea 27(10):1195\u20131199","journal-title":"Cornea"},{"issue":"9","key":"9807_CR3","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/ICO.0b013e31819839f9","volume":"28","author":"JY Oh","year":"2009","unstructured":"Oh JY, Kim MK, Wee WR (2009) Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy. Cornea 28(9):1070\u20131073","journal-title":"Cornea"},{"issue":"10","key":"9807_CR4","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/ICO.0b013e31821379aa","volume":"30","author":"SN Yeung","year":"2011","unstructured":"Yeung SN, Lichtinger A, Kim P, Amiran MD, Slomovic AR (2011) Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization. Cornea 30(10):1110\u20131114","journal-title":"Cornea"},{"issue":"6","key":"9807_CR5","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/ICO.0b013e3181ba0ae2","volume":"29","author":"RJ Symes","year":"2010","unstructured":"Symes RJ, Poole TR (2010) Corneal graft surgery combined with subconjunctival bevacizumab (avastin). Cornea 29(6):691\u2013693","journal-title":"Cornea"},{"issue":"5","key":"9807_CR6","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1177\/112067210901900530","volume":"19","author":"S Saxena","year":"2009","unstructured":"Saxena S, Kishore P, Pandey S, Khattri M, Kumar D (2009) Topical bevacizumab for corneal neovascularization after penetrating keratoplasty. Eur J Ophthalmol 19(5):870\u2013872","journal-title":"Eur J Ophthalmol"},{"issue":"8","key":"9807_CR7","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1755-3768.2009.01585.x","volume":"88","author":"AA Zaki","year":"2010","unstructured":"Zaki AA, Farid SF (2010) Subconjunctival bevacizumab for corneal neovascularization. Acta Ophthalmol 88(8):868\u2013871","journal-title":"Acta Ophthalmol"},{"issue":"9","key":"9807_CR8","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ICO.0b013e31817786ad","volume":"27","author":"PP Doctor","year":"2008","unstructured":"Doctor PP, Bhat PV, Foster CS (2008) Subconjunctival bevacizumab for corneal neovascularization. Cornea 27(9):992\u2013995","journal-title":"Cornea"},{"issue":"6","key":"9807_CR9","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/QAI.0b013e31815b833a","volume":"27","author":"MA Carrasco","year":"2008","unstructured":"Carrasco MA (2008) Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis. Cornea 27(6):743\u2013745","journal-title":"Cornea"},{"issue":"6","key":"9807_CR10","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","volume":"115","author":"SW Kim","year":"2008","unstructured":"Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI (2008) The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 115(6):e33\u2013e38","journal-title":"Ophthalmology"},{"issue":"2","key":"9807_CR11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/ICO.0b013e318159019f","volume":"27","author":"I Bahar","year":"2008","unstructured":"Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A (2008) Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 27(2):142\u2013147","journal-title":"Cornea"},{"issue":"9","key":"9807_CR12","first-page":"2514","volume":"41","author":"W Philipp","year":"2000","unstructured":"Philipp W, Speicher L, Humpel C (2000) Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 41(9):2514\u20132522","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"9807_CR13","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/ICO.0b013e3180de1d0a","volume":"26","author":"E Yoeruek","year":"2007","unstructured":"Yoeruek E, Spitzer MS, Tatar O, Aisenbrey S, Bartz-Schmidt KU, Szurman P (2007) Safety profile of bevacizumab on cultured human corneal cells. Cornea 26(8):977\u2013982","journal-title":"Cornea"},{"issue":"7114","key":"9807_CR14","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nature05249","volume":"443","author":"BK Ambati","year":"2006","unstructured":"Ambati BK, Nozaki M, Singh N et al (2006) Corneal avascularity is due to soluble VEGF receptor-1. Nature 443(7114):993\u2013997","journal-title":"Nature"},{"issue":"5","key":"9807_CR15","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1600-0420.2004.00312.x","volume":"82","author":"L Gan","year":"2004","unstructured":"Gan L, Fagerholm P, Palmblad J (2004) Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand 82(5):557\u2013563","journal-title":"Acta Ophthalmol Scand"},{"issue":"11","key":"9807_CR16","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00347-007-1569-y","volume":"104","author":"M Kernt","year":"2007","unstructured":"Kernt M, Welge-Lussen U, Yu A, Neubauer AS, Kamplik A (2007) Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells. Ophthalmologe 104(11):965\u2013971","journal-title":"Ophthalmologe"},{"issue":"8","key":"9807_CR17","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/IJG.0b013e3181996ed2","volume":"18","author":"JP Shin","year":"2009","unstructured":"Shin JP, Lee JW, Sohn BJ, Kim HK, Kim SY (2009) In vivo corneal endothelial safety of intracameral bevacizumab and effect in neovascular glaucoma combined with Ahmed valve implantation. J Glaucoma 18(8):589\u2013594","journal-title":"J Glaucoma"},{"issue":"8","key":"9807_CR18","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/ICO.0b013e3181ca33d2","volume":"29","author":"C Perez-Rico","year":"2010","unstructured":"Perez-Rico C, Benitez-Herreros J, Castro-Rebollo M et al (2010) Effect of intravitreal ranibizumab on corneal endothelium in age-related macular degeneration. Cornea 29(8):849\u2013852","journal-title":"Cornea"},{"issue":"5","key":"9807_CR19","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ajo.2008.06.002","volume":"146","author":"CC Chiang","year":"2008","unstructured":"Chiang CC, Chen WL, Lin JM, Tsai YY (2008) Effect of bevacizumab on human corneal endothelial cells: a six-month follow-up study. Am J Ophthalmol 146(5):688\u2013691","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"9807_CR20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3109\/09273948.2010.490630","volume":"18","author":"SA Bayar","year":"2010","unstructured":"Bayar SA, Altinors DD, Kucukerdonmez C, Akova YA (2010) Severe corneal changes following intravitreal injection of bevacizumab. Ocul Immunol Inflamm 18(4):268\u2013274","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"9807_CR21","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1089\/jop.2009.0056","volume":"25","author":"MH Hosny","year":"2009","unstructured":"Hosny MH, Zayed MA, Shalaby AM, Eissa IM (2009) Effect of intracameral bevacizumab injection on corneal endothelial cells: an in vivo evaluation. J Ocul Pharmacol Ther 25(6):513\u2013517","journal-title":"J Ocul Pharmacol Ther"},{"issue":"10","key":"9807_CR22","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.ophtha.2007.05.016","volume":"114","author":"H Harooni","year":"2007","unstructured":"Harooni H, Reddy V, Root T, Ambati B (2007) Bevacizumab for graft rejection. Ophthalmology 114(10):1950","journal-title":"Ophthalmology"},{"issue":"10","key":"9807_CR23","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00417-007-0587-4","volume":"245","author":"M Erdurmus","year":"2007","unstructured":"Erdurmus M, Totan Y (2007) Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 245(10):1577\u20131579","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"9807_CR24","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/j.jcrs.2007.07.012","volume":"33","author":"A Awadein","year":"2007","unstructured":"Awadein A (2007) Subconjunctival bevacizumab for vascularized rejected corneal grafts. J Cataract Refract Surg 33(11):1991\u20131993","journal-title":"J Cataract Refract Surg"},{"issue":"1","key":"9807_CR25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/02713680701799101","volume":"33","author":"I Bahar","year":"2008","unstructured":"Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A (2008) Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res 33(1):23\u201328","journal-title":"Curr Eye Res"},{"issue":"3","key":"9807_CR26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000252980","volume":"43","author":"MR Razeghinejad","year":"2010","unstructured":"Razeghinejad MR, Hosseini H, Ahmadi F, Rahat F, Eghbal H (2010) Preliminary results of subconjunctival bevacizumab in primary pterygium excision. Ophthalmic Res 43(3):134\u2013138","journal-title":"Ophthalmic Res"},{"issue":"3","key":"9807_CR27","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/ICO.0b013e31822480f9","volume":"31","author":"H Hosseini","year":"2012","unstructured":"Hosseini H, Nowroozzadeh MH, Salouti R, Nejabat M (2012) Anti-VEGF therapy with bevacizumab for anterior segment eye disease. Cornea 31(3):322\u2013334","journal-title":"Cornea"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-013-9807-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-013-9807-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-013-9807-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,14]],"date-time":"2019-07-14T03:27:00Z","timestamp":1563074820000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-013-9807-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,31]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["9807"],"URL":"https:\/\/doi.org\/10.1007\/s10792-013-9807-6","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,31]]}}}